Asthma, one of the significant public health problems, is triggered by certain inflammatory processes in the airways that are not addressed propitiously by current therapies. Though pieces of evidence on allergic asthma mitigation by the anti-inflammatory bioflavonoid chrysin (CHR) are accumulating, poor bioavailability, and low solubility curtail drug development. To overcome these shortcomings, CHR loaded nanoparticle (CHR-NP) was formulated, and its salutary effect in preclinical murine allergic asthma model via the peroral route was evaluated. The spherical nanosized particles showed slow, sustained release in vitro. Moreover, CHR-NP dramatically reduced the serum IgE, ovalbumin (OVA)-induced lung histological alteration, as well as Th2 (T-helper 2) cytokines in the bronchoalveolar lavage fluid (BALF). It also suppressed the elevated serum pro-inflammatory cytokines and their upstream TLR/NF-κB/NLRP3 pathway activation in lung superior to CHR and almost identical to dexamethasone (DEX). Thus this study suggests the potentiality of CHR-NP in ameliorating allergic asthma progression.

哮喘是重要的公共健康问题之一，它是由气道中的某些炎症过程引发的，而当前的疗法并没有很好地解决这些炎症过程。尽管关于抗炎生物类黄酮白杨素 (CHR) 缓解过敏性哮喘的证据正在积累，但生物利用度差和溶解度低会限制药物开发。为了克服这些缺点，制备了载有 CHR 的纳米颗粒 (CHR-NP)，并评估了其通过口服途径在临床前小鼠过敏性哮喘模型中的有益作用。球形纳米颗粒在体外表现出缓慢、持续的释放。此外，CHR-NP 显着降低了支气管肺泡灌洗液 (BALF) 中的血清 IgE、卵清蛋白 (OVA) 诱导的肺组织学改变以及 Th2（T 辅助 2）细胞因子。它还抑制肺中升高的血清促炎细胞因子及其上游 TLR/NF-κB/NLRP3 通路激活，优于 CHR，几乎与地塞米松 (DEX) 相同。因此，这项研究表明 CHR-NP 在改善过敏性哮喘进展方面的潜力。